一年一度的全球肿瘤界盛会-美国临床肿瘤学会（ASCO）年会将于当地时间6月2日-6月6日召开。ASCO年会是世界上规模最大、学术水平最高、最具权威的临床肿瘤学会议，致力于癌症的预防、治疗和改善患者管理，以展示肿瘤的基础研究和临床最新研究为特点，讨论当前国际先进的治疗方法。随着中国临床研究在肿瘤领域的快速成长，中国在世界肿瘤领域中也发挥着日益重要的作用。此次会议上，中国研究Oral Abstract Session共入选19项，另外Clinical Science Symposium和Rapid Abstract Session部分各有1项中国研究入选。期待中国专家在ASCO年会上展现风采！

癌症照护和管理策略

Care Delivery and Regulatory Policy

摘要号：1500

标题：AI blood signature in common blood tests for detection of gastric cancer in a cohort of 190,000 individuals

报告人：Tsz Chun Bryan Wong, MPhil

单位：香港科技大学

在研疗法-免疫治疗

Developmental Therapeutics—Immunotherapy

摘要号：2507

标题：Phase I study of the bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 combined with SHR2554, an EZH2 inhibitor, in patients with previously treated advanced lymphoma and solid tumors.

报告人：丰恺超

单位：解放军总医院第一医学中心

在研疗法-分子靶向药物和肿瘤生物学

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

摘要号：3001

标题：BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study.

报告人：张力

单位：中山大学肿瘤防治中心

摘要号：3007

标题：A phase I study of KL590586, a next-generation selective RET inhibitor, in patients with RET-altered solid tumors.

报告人：周清

单位：广东省人民医院

胃肠道肿瘤-结直肠癌和肛门癌

Gastrointestinal Cancer—Colorectal and Anal

摘要号：3505

标题：Long-term outcome of neoadjuvant mFOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: A multicenter, randomized phase III trial.

报告人：张剑威

单位：中山大学附属第六医院

胃肠道肿瘤-胃食管癌、胰腺癌和肝胆癌

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

摘要号：4001

标题：Perioperative PD-1 antibody toripalimab plus SOX or XELOX chemotherapy versus SOX or XELOX alone for locally advanced gastric or gastro-oesophageal junction cancer: Results from a prospective, randomized, open-label, phase II trial.

报告人：袁庶强

单位：中山大学肿瘤防治中心

摘要号：4004

标题：Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC).

报告人：George Lau

单位：香港天下仁心医疗集团

妇科肿瘤

Gynecologic Cancer

摘要号：5516

标题：Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy: A single-arm phase II trial.

报告人：田文娟

单位：复旦大学附属肿瘤医院

头颈肿瘤

Head and Neck Cancer

摘要号：6000

标题：Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-5-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: A multicentre, open-label, randomised, controlled, phase 3 trial.

报告人：唐林泉

单位：中山大学肿瘤防治中心

摘要号：6001

标题：Induction chemotherapy plus radiotherapy alone versus cisplatin-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: An open-label, non-inferiority, randomized phase 3 trial.

报告人：陈明远

单位：中山大学肿瘤防治中心

摘要号：LBA6002

标题：PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM).

报告人：马骏

单位：中山大学肿瘤防治中心

血液系统恶性肿瘤-淋巴瘤和慢性淋巴细胞白血病

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

摘要号：7503

标题：Golidocitinib in treating refractory or relapsed peripheral T-cell lymphoma: Primary analysis of the multinational pivotal study results (JACKPOT8).

报告人：蔡清清

单位：中山大学肿瘤防治中心

血液系统恶性肿瘤-浆细胞疾病

Hematologic Malignancies—Plasma Cell Dyscrasia

摘要号：8005

标题：Updated results of a phase I, open-label study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM).

报告人：杜鹃

单位：上海长征医院

肺癌-非小细胞局部-区域性/小细胞/其他胸部肿瘤

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

摘要号：8501

标题：Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III NEOTORCH study.

报告人：陆舜

单位：上海交通大学医学院附属胸科医院

肺癌-转移性非小细胞肺癌

Lung Cancer—Non-Small Cell Metastatic

摘要号：LBA9000

标题：Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study.

报告人：James Chih-Hsin Yang, MD, PhD

单位：台湾大学医学院附属医院

摘要号：9001

标题：Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis.

报告人：吴一龙

单位：广东省人民医院

摘要号：9002

标题：Sunvozertinib for the treatment of NSCLC with EGFR Exon20 insertion mutations: The first pivotal study results.

报告人：王孟昭

单位：北京协和医院

摘要号：9003

标题：Final overall survival and biomarker analyses of CHOICE-01: A double-blind randomized phase 3 study of toripalimab versus placebo in combination chemotherapy for advanced NSCLC without EGFR/ALK mutations.

报告人：邬麟

单位：湖南省肿瘤医院

黑色素瘤/皮肤癌

Melanoma/Skin Cancers

摘要号：9508

标题：Temozolomide plus cisplatin versus toripalimab (anti-PD-1) as adjuvant therapy in resected mucosal melanoma.

报告人：郭军

单位：北京大学肿瘤医院

快速摘要报告

Rapid Abstract Session

摘要号：LBA1013

标题：TORCHLIGHT: a randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel(nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC).

报告人：江泽飞

单位：解放军总医院第五医学中心

临床科学研讨会

Clinical Science Symposium

摘要号：11510

标题：The clinical value of tumor-informed minimal residual disease detection in sarcoma.

报告人：尹军强

单位：中山大学附属第一医院

备注：排名不分先后，按照摘要号进行

如有遗漏或任何问题，请给我们留言~